Clinical utility of intravitreal fluocinolone acetonide (Iluvien®) implant in the management of patients with chronic diabetic macular edema: a review of the current literature
Habiba Saedon,1 Astha Anand,1 Yit C Yang1,2 1Department of Ophthalmology, Royal Wolverhampton NHS Trust, Wolverhampton, West Midlands, 2School of Life and Health Sciences, Aston University, Birmingham, UK Abstract: The first-line therapy for patients with center-involving diabetic macular edema (D...
Enregistré dans:
Auteurs principaux: | Saedon H, Anand A, Yang YC |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2017
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/b57e9a38a3f64c3da7e9b3e998795f02 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Clinical-Decision Criteria to Identify Recurrent Diabetic Macular Edema Patients Suitable for Fluocinolone Acetonide Implant Therapy (ILUVIEN®) and Follow-Up Considerations/Recommendations
par: Adán A, et autres
Publié: (2020) -
Efficacy and safety of sustained-delivery fluocinolone acetonide intravitreal implant in patients with chronic diabetic macular edema insufficiently responsive to available therapies: a real-life study
par: Massin P, et autres
Publié: (2016) -
Real-world retrospective comparison of 0.19 mg fluocinolone acetonide and 0.7 mg dexamethasone intravitreal implants for the treatment of diabetic macular edema in vitrectomized eyes
par: Coelho J, et autres
Publié: (2019) -
Real-World Outcomes in Diabetic Macular Edema for the 0.2 μg/Day Fluocinolone Acetonide Implant: Case Series from the Midlands, UK
par: Mushtaq B, et autres
Publié: (2021) -
Rapid Structural and Functional Improvements with the 0.19 mg Fluocinolone Acetonide Intravitreal Implant for Patients with DME and Low Visual Acuity: 6-Month Data from the UAE
par: Elbarky AM
Publié: (2020)